The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Pooled result · DeathResult — go to the resultHazard ratio 1.28 95 % CI 1.14–1.44Authors' conclusion
Diabetes compromises the effectiveness of ICI treatment in patients with NSCLC.
Study context
- Population
- Patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)10 non-randomized studies
- Comparison
- Diabetes vs no diabetes in patients with NSCLC receiving ICIs
- Outcome
- Overall survival (hazard of death)
Methodological detailssubgroup, meta-regression and sensitivity analyses
- Subgroup, meta-regression and sensitivity analyses
Pooled result
Death
Hazard ratio
1.28
95 % CI 1.14–1.44
P < 0.01
Diabetesvs No diabetes
HR 1.28 (95 % CI 1.14–1.44); P < 0.01
As reported in the abstract
Further pooled results
| Outcome | Difference (months) (95 % CI) | P value |
|---|---|---|
| Median life expectancyShorter with Diabetes | 6.04 (−10.53 to - 1.54) | P = 0.009 |
PFS HR by proportion of diabetes patients using metformin (meta-regression)
- Decrease in HR of PFS per 1 % increase in proportion using metformin
- 2.2 % (95 % CI = 1.2-3.1 %)
Original publication
The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Diabetes Res Clin Pract. Published 12 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →